Nanion Technologies, a leading provider of automated patch clamp platforms, and Axion Biosystems, originator of the first high throughput microelectrode array system, today announce a distribution partnership in Europe and China. Nanion will immediately carry Axion’s MEA-products, supporting a broad range of biomedical applications.
Axion Biosystems provides state-of-the-art, high resolution, MEA based instruments for experiments ranging from basic cellular electrophysiology to high throughput screening (HTS). Axion’s MEA systems represent the next generation in multielectrode array technology, providing unprecedented access to native cellular electrical signaling and connectivity. To meet the growing demand for “disease in a dish” assays and functional safety screening, Axion and Nanion today announced a strategic distribution partnership for the European and Chinese markets.
Further strengthening and complementing the Nanion product portfolio, Nanion will distribute, service, and support the Axion single-well MEA system, the Muse, and the Maestro, a multiwell MEA system with HTS capabilities.
Dr. Niels Fertig, CEO and founder of Nanion Technologies, says: “We are extremely impressed by Axion’s MEA-systems because of their broad scope of applications, ranging from in-depth, highly resolved cellular network behavior to high throughput drug screening. We think that Axions’s products provide an excellent complement to our automated patch clamp screening and impedance-based systems, and see great potential for applications including phenotype screening, stem cells as tools for phenotypic disease models, and of course, safety, neuro- and cardiotoxicity testing. Additionally, the partnership with Axion will further strengthen us as the one-stop-shop for proficient tools for electrophysiology drug research, screening and intersecting areas.”
Tom O’Brien, CEO of Axion Biosystems, continues: “Nanion is a great match for Axion, since we share the same background and philosophy, ultimately manifested in innovative products. As companies, we both have a solid research- and application-driven focus, as well as a deep understanding and broad expertise in science and technical development. These characteristics are combined with a vision to push the boundaries toward HTS-compatible products. We were attracted to Nanion’s strong track record of growth, and their excellent reputation for customer service and product reliability. We are excited about this partnership and have great confidence that Nanion will be very successful as our sales and distribution partner for the European and Chinese markets.”
Nanion Technologies and Axion Biosystems will be displaying their products together at the MEA-meeting in Reutlingen, Germany, July 1-4, 2014, and at the FENS 2014 meeting in Milan, Italy, July 4-7, 2014.
Axion Biosystems provides state-of-the-art, high resolution, MEA based instruments for experiments ranging from basic cellular electrophysiology to high throughput screening (HTS). Axion’s MEA systems represent the next generation in multielectrode array technology, providing unprecedented access to native cellular electrical signaling and connectivity. To meet the growing demand for “disease in a dish” assays and functional safety screening, Axion and Nanion today announced a strategic distribution partnership for the European and Chinese markets.
Further strengthening and complementing the Nanion product portfolio, Nanion will distribute, service, and support the Axion single-well MEA system, the Muse, and the Maestro, a multiwell MEA system with HTS capabilities.
Dr. Niels Fertig, CEO and founder of Nanion Technologies, says: “We are extremely impressed by Axion’s MEA-systems because of their broad scope of applications, ranging from in-depth, highly resolved cellular network behavior to high throughput drug screening. We think that Axions’s products provide an excellent complement to our automated patch clamp screening and impedance-based systems, and see great potential for applications including phenotype screening, stem cells as tools for phenotypic disease models, and of course, safety, neuro- and cardiotoxicity testing. Additionally, the partnership with Axion will further strengthen us as the one-stop-shop for proficient tools for electrophysiology drug research, screening and intersecting areas.”
Tom O’Brien, CEO of Axion Biosystems, continues: “Nanion is a great match for Axion, since we share the same background and philosophy, ultimately manifested in innovative products. As companies, we both have a solid research- and application-driven focus, as well as a deep understanding and broad expertise in science and technical development. These characteristics are combined with a vision to push the boundaries toward HTS-compatible products. We were attracted to Nanion’s strong track record of growth, and their excellent reputation for customer service and product reliability. We are excited about this partnership and have great confidence that Nanion will be very successful as our sales and distribution partner for the European and Chinese markets.”
Nanion Technologies and Axion Biosystems will be displaying their products together at the MEA-meeting in Reutlingen, Germany, July 1-4, 2014, and at the FENS 2014 meeting in Milan, Italy, July 4-7, 2014.
